Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Eli Lilly LLY remains a dominant player in the global obesity market, with much of its recent growth driven by itsblockbuster ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12 ...

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

Eli Lilly's soaring stock price has sparked 2026 split speculation. Here's what a potential LLY split could mean and what investors should consider now.

Eli Lilly (LLY) stock drops as HSBC downgrades the company warning that weight-loss drugmaker could be “priced to perfection.

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even dominant corporations are susceptible to sharp..

Eli Lilly (LLY) stock declined after HSBC downgrade to Reduce with $850 price target, citing obesity drug market risks and ...

Eli Lilly (LLY) stock is lower today, after HSBC downgraded it to "reduce" from "hold," citing an inflated obesity drug market ...

Lilly shares are still up about 14% over the last 12 months, sharply outperforming rival Novo Nordisk, whose stock has declined more than 54% over the same period. HSBC analyst Rajesh Kumar downgraded ...

HSBC analysts just slashed their recommendation on the world's most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to ...